CoChat

Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients.

Rebelatto, Marlon, Mistry, Amita, Sabalos, Costi, Walker, Jill, Midha, Anita, Steele, Keith, Robbins, Paul B., Li, Xia, Shi, Li, Blake-Haskins, John A., Ibrahim, Ramy A., Richman, Laura · 2015 · Journal of Clinical Oncology
Cited by 29

The DOI matches its Crossref record.

Abstract

8033 Background: A high quality PD-L1 companion diagnostic may help predict which patients are more likely to respond to PD-1/PD-L1 antibody-based therapy. Here we describe a PD-L1 immunohistochemical (IHC) diagnostic test developed by Ventana Medical Systems for use with MEDI4736. Methods: An anti-human PD-L1 rabbit monoclonal antibody (SP263) was optimized for use with Ventana OptiView DAB IHC Detection Kit on the automated BenchMark ULTRA platform. The PD-L1 IHC assay was validated for use in formalin-fixed, paraffin-embedded samples of NSCLC and SCCHN in a series of studies addressing sensitivity, specificity, robustness, and precision. MEDI4736 is a human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80 with high affinity and selectivity. A subset of clinical trial samples from a Phase 1/2 study of MEDI4736 (NCT01693562) was analyzed to determine optimal cut-off for enriching response to MEDI4736. Inter-reader precision was established by 3 pathologists who evaluated 81 NSCLC and 100 SCCHN samples across the range of expression levels. Results: The Ventana PD-L1 IHC (SP263) assay met all pre-defined acceptance criteria. The scoring algorithm was defined using statistical analysis of clinical response data and PD-L1 staining parameters observed in a set of NCT01693562 clinical trial samples. Samples of both cancer types are considered test positive when the membrane of ≥ 25% of tumor cells stain for PD-L1 at any intensity. Inter-reader precision in determining PD-L1 status resulted in an overall percentage agreement of 97% and 92% for NSCLC and SCCHN, respectively. For both NSCLC and SCCHN, PD-L1+ patients identified by the scoring algorithm had a higher response rate than PD-L1- patients. Conclusions: These results highlight the robustness and reproducibility of the PD-L1 IHC (SP263) assay in a clinical setting. In NSCLC and SCCHN patients treated with MEDI4736, PD-L1+ patients identified by the scoring algorithm had a higher response rate than PD-L1- patients. The clinical utility of the PD-L1 diagnostic assay will be further validated in a prospective manner using additional patients in this study and in other MEDI4736 studies. Clinical trial information: NCT01693562.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.33.15_suppl.8033

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 29

Metadata

Authors
Rebelatto, M., Mistry, A., Sabalos, C., Walker, J., Midha, A., Steele, K., Robbins, P. B., Li, X., Shi, L., Blake-Haskins, J. A., Ibrahim, R. A., & Richman, L.
Venue
Journal of Clinical Oncology
Published
2015-05-20
Volume
33
Issue
15_suppl
Pages
8033-8033
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2243285944
Cited by
29
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients. https://app.cochat.ai/papers/10.1200/jco.2015.33.15_suppl.8033
The paper
Rebelatto, M., Mistry, A., Sabalos, C., Walker, J., Midha, A., Steele, K., Robbins, P. B., Li, X., Shi, L., Blake-Haskins, J. A., Ibrahim, R. A., & Richman, L. (2015). Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.33.15_suppl.8033

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.